Correction Previously Distributed Press Release SciBase Holding AB (publ)

Year-end Report 2018

STOCKHOLM, Feb. 20, 2019 /PRNewswire/ --

January 1 – December 31, 2018

The fourth quarter in figures

• Net sales amounted to TSEK 2,030 (1,886).

• The loss after tax amounted to TSEK 11,506 (10,295).

• The loss per share amounted to SEK 0.69 (1.13).

• The cash flow from current operations was negative in the amount of TSEK 9,990 (11,358).

• The gross margin increased to 52.1% (31,5%).

• Electrode sales in volume decreased by 2% and reached 3,872 (3,936) units. Repeat sales of electrodes to existing customers increased by 6%.

The full year in figures

• Net sales amounted to TSEK 6,899 (6,859).

• The loss after tax amounted to TSEK 44,215 (42,464).

• The loss per share amounted to SEK 2.66 (5.00).

• The cash flow from current operations was negative in the amount of TSEK 37,482 (44,180). 

• The gross margin increased to 52.0% (35.4%).

• Electrode sales in volume decreased by 7% and reached 15,478 (16,704) units. Repeat sales of electrodes were at the same level as 2017.

Important events during the quarter

• Sales on the company's key market Germany increased by 41% in the quarter driven by system sales to new customers. 

• A new German clinical guideline supported by Onkoderm was published. The guidelines support the use of Nevisense in the evaluation of lesions with suspicion of melanoma and also include a recommendation for reimbursement. 

• SciBase and the Swiss Institute of Allergy and Asthma Research, Davos Switzerland (SIAF-SFI) announced the signing of a formal collaboration agreement within the area of barrier function testing using Electrical Impedance Spectroscopy (EIS). In addition the partners have jointly filed a patent application covering the use of electrical impedance testing for the evaluation of epithelial barrier function, potentially a unique tool to help address some of the most common disorders such as eczema, food allergy, allergic rhinitis and asthma.  

• A new US study was published online in the Journal of the American Academy of Dermatology (JAAD) that showed good potential for Nevisense to improve clinical decision-making.

• The Company participated in the Fall Clinical meeting in Las Vegas.

• A nominating committee was appointed

Important events after the end of the period